Cytogen nominates Lokay as president, CEO

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Cytogen, a biopharmaceutical company for oncology products, has named Kevin Lokay president and chief executive officer, effective immediately.

Lokay, a member of the board of directors for the past six years, succeeds Michael Becker who resigned to pursue another executive position, according to the Princeton, N.J.-based company.

Cytogean also said that Lokay brings more than 26 years of pharmaceutical industry experience to the company’s executive management team.